RSV prevention drug beyfortus under safety watch in 3,000 korean kids
NCT ID NCT07200206
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times
Summary
This study is a safety check for Beyfortus, a medicine given to children up to 24 months old to prevent RSV, a serious lung infection. Researchers will watch 3,000 children in Korea for 180 days after they get the drug to see if any side effects occur. The goal is to make sure the medicine is safe in real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nam Seung Woo Pediatric: 4100007
RECRUITINGHwaseong-si, Gyeonggi-do, 18478, South Korea
Conditions
Explore the condition pages connected to this study.